Takeda fosters a collaborative and stimulating work environment filled with opportunity and the chance to make a difference in people's lives. It is a workplace driven by integrity, one of Takeda’s long-held values that extends to both the patients we serve and our employees who develop and deliver medicines. Across our company, Takeda employees bring together diverse strengths that together create a stronger whole.
I am currently the Product Operations Lead for enzyme replacement therapies to treat rare metabolic diseases, and it’s my job to ensure that our manufacturing and supply strategies enable the supply of our drug products to patients around the world. I work cross-functionally with master planning, Biologics Operating Units, Quality, Regulatory and other departments and local operating committees to help build launch strategies in different countries.
T-CiRA is a 10-year-long joint research program between Takeda and Kyoto University's Center for iPS Cell Research and Application (CiRA) led by Prof. Shinya Yamanaka, a Nobel Prize-winning researcher. T-CiRA is engaged in cutting-edge research into the clinical applications of iPS (induced pluripotent stem) cell technology. The team is working on the development of regenerative medicine and drug discovery, determined to provide patients with innovative treatment methods.
Clinical Operations teams play a critical role in the development of new treatments. Responsible for operational management of clinical trials, they are at the center of the lengthy process of taking a drug candidate through all phases to become an approved treatment available to patients.
After surgery, radiotherapy and chemotherapy, a fourth method of treating cancer is gaining increasing attention: immunotherapy. At Takeda’s research center in Boston, a large team of researchers is working hard to develop new treatments based on this cutting-edge approach.
I work in clinical development, a role in which I focus on a particular pharmaceutical drug and investigate how to move it forward for the benefit of patients. That might mean designing trials to receive approval by one of the regulatory agencies or, if it’s already been approved, looking at how it can be improved further to make it even more valuable for patients.
Takeda’s internal auditors assess, report and provide recommendations for improvements on the Takeda Group governance, risk management and internal control processes of all the company’s domestic and international entities. This is a crucial part of improving business operations and keeping the organization healthy.
The role of investor relations (IR) is to keep shareholders and investors informed so that they can make investment decisions with confidence. Through that, the value of the company can then be evaluated appropriately. When challenging situations arise, its true merit is put to the test.
At Takeda there is a role called a Medical Science Liaison (MSL), a job that involves listening to doctors who see patients on a daily basis and paving the way to better treatments for symptoms that are not addressed by current medicines.
My job involves working with international organizations to develop policies that improve access to medicines for people worldwide.
Our work begins with the need to solve a problem, then quickly becomes a mission: to develop medicines that can help patients.
I’m a drug discovery chemist. I lead a team that designs and synthesizes drug candidates, and our goal is to become the best team of our kind in the world.
T-CiRA is a joint research program conducted with the Kyoto University Center for iPS Cell Research and Application (CiRA). Researchers share what drives them in their work on cutting-edge projects.
I am in charge of our drug substance manufacturing processes.
I am in charge of the marketing for an anticancer drug, for multiple myeloma.